Centrient Pharmaceuticals, headquartered in the Netherlands, is a leading player in the global pharmaceutical industry, specialising in the development and manufacturing of essential antibiotics and anti-infectives. Founded in 2017, the company has quickly established itself as a key provider of high-quality, sustainable pharmaceutical solutions, with a strong operational presence across Europe, Asia, and North America. Centrient's core offerings include a diverse range of generic and branded antibiotics, as well as innovative formulations that address critical healthcare needs. The company is recognised for its commitment to sustainability and responsible manufacturing practices, setting it apart in a competitive market. With a focus on quality and patient safety, Centrient Pharmaceuticals continues to achieve significant milestones, reinforcing its position as a trusted partner in the healthcare sector.
How does Centrient Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Centrient Pharmaceuticals's score of 37 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Centrient Pharmaceuticals reported total carbon emissions of approximately 142,740,000 kg CO2e for Scope 1, 141,369,000 kg CO2e for Scope 2, and 448,232,000 kg CO2e for Scope 3 emissions. The combined total for Scope 1 and 2 emissions was about 284,109,000 kg CO2e. This reflects a slight increase in Scope 1 emissions from 2022, which were approximately 136,647,000 kg CO2e, while Scope 2 emissions decreased from 145,606,000 kg CO2e in the previous year. Centrient Pharmaceuticals has set ambitious climate commitments, aiming for a 35% reduction in carbon emission intensity by 2025 and a 50% reduction by 2030. Additionally, the company has committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by 2031, using 2022 as the base year. For Scope 3 emissions, specifically from purchased goods and services and fuel and energy-related activities, a target of 27.5% reduction has been established for the same timeframe. These targets align with industry standards and reflect Centrient's commitment to addressing climate change and reducing its carbon footprint across all scopes of emissions.
Access structured emissions data, company-specific emission factors, and source documents
2021 | 2022 | 2023 | |
---|---|---|---|
Scope 1 | 87,494,000 | 000,000,000 | 000,000,000 |
Scope 2 | 202,885,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Centrient Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.